-
1
-
-
84878375924
-
-
PID: 23725711, COI: 1:CAS:528:DC%2BC3sXosVOntL8%3D
-
Abou-Alfa GK, Venook AP (2013) The antiangiogenic ceiling in hepatocellular carcinoma: does it exist and has it been reached? Lancet Oncol 14:e283–e288
-
(2013)
Lancet Oncol
, vol.14
, pp. e283
-
-
Abou-Alfa1
-
2
-
-
84901340078
-
-
PID: 24577748, COI: 1:CAS:528:DC%2BC2cXosFahsLY%3D
-
Ackerman A, Klein O, McDermott DF et al (2014) Outcomes of patients with metastatic melanoma treated with immunotherapy prior to or after BRAF inhibitors. Cancer 120:1695–1701
-
(2014)
Cancer
, vol.120
, pp. 1695
-
-
Ackerman1
-
3
-
-
84868329937
-
-
PID: 22941024
-
Ang C, O’Reilly EM, Abou-Alfa GK (2013) Targeted agents and systemic therapy in hepatocellular carcinoma. Recent Results Cancer Res 190:225–246
-
(2013)
Recent Results Cancer Res
, vol.190
, pp. 225
-
-
Ang1
-
4
-
-
84899112560
-
-
PID: 24701370
-
Aranda F, Vacchelli E, Eggermont A et al (2014) Trial watch: immunostimulatory monoclonal antibodies in cancer therapy. Oncoimmunology 3:e27297
-
(2014)
Oncoimmunology
, vol.3
, pp. e27297
-
-
Aranda1
-
5
-
-
84887072136
-
-
PID: 23958310, COI: 1:CAS:528:DC%2BC3sXht12itbjF
-
Bahl A, Masson S, Birtle A et al (2014) Second-line treatment options in metastatic castration-resistant prostate cancer: a comparison of key trials with recently approved agents. Cancer Treat Rev 40:170–177
-
(2014)
Cancer Treat Rev
, vol.40
, pp. 170
-
-
Bahl1
-
6
-
-
84910132838
-
-
PID: 24685918, COI: 1:CAS:528:DC%2BC2cXlslSlsL8%3D
-
Bergmann L, Beck J, Bothe K et al (2014) Treatment algorithm for metastatic renal cell carcinoma – recommendations based on evidence and clinical practice. Oncol Res Treat 37:136–141
-
(2014)
Oncol Res Treat
, vol.37
, pp. 136
-
-
Bergmann1
-
7
-
-
84873864130
-
-
Brady D, Parker CC, O’Sullivan JM (2013) Bone-targeting radiopharmaceuticals including radium-223. Cancer J 19:71–78
-
(2013)
Cancer
, vol.J
, pp. 71
-
-
Brady1
-
8
-
-
84878901004
-
-
PID: 23552469, COI: 1:CAS:528:DC%2BC3sXnvVKqsLc%3D
-
Buti S, Bersanelli M, Sikokis A et al (2013) Chemotherapy in metastatic renal cell carcinoma today? A systematic review. Anticancer Drugs 24:535–554
-
(2013)
Anticancer Drugs
, vol.24
, pp. 535
-
-
Buti1
-
9
-
-
84877824937
-
Update of epidermal growth factor receptor-tyrosine kinase inhibitors in non-small-cell lung cancer
-
Chen YM (2013) Update of epidermal growth factor receptor-tyrosine kinase inhibitors in non-small-cell lung cancer. J Chin Med Assoc 76:249–257
-
(2013)
J Chin Med Assoc
, vol.76
, pp. 249-257
-
-
Chen, Y.M.1
-
10
-
-
84879446651
-
-
PID: 23529824, COI: 1:CAS:528:DC%2BC3sXhvVWmtbjP
-
Dhillon S (2013) Everolimus in combination with exemestane: a review of its use in the treatment of patients with postmenopausal hormone receptor-positive, HER2-negative advanced breast cancer. Drugs 73:475–485
-
(2013)
Drugs
, vol.73
, pp. 475
-
-
Dhillon1
-
11
-
-
84898057419
-
-
COI: 1:CAS:528:DC%2BC2cXis1Sjsrk%3D
-
Freiwald M, Schmid U, Fleury A et al (2014) Population pharmacokinetics of afatinib, an irreversible ErbB family blocker, in patients with various solid tumors. Cancer Chemother Pharmacol 73:759–770
-
(2014)
Cancer Chemother Pharmacol
, vol.73
, pp. 759
-
-
Freiwald1
-
12
-
-
84872921660
-
-
PID: 23177514, COI: 1:CAS:528:DC%2BC38Xhslarsr%2FE
-
Grothey A, Van Cutsem E, Sobrero A et al (2013) Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 381:303–312
-
(2013)
Lancet
, vol.381
, pp. 303
-
-
Grothey1
-
13
-
-
84864285704
-
-
PID: 22735384, COI: 1:CAS:528:DC%2BC38Xpt1SgtLg%3D
-
Hauschild A, Grob JJ, Demidov LV et al (2012) Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet 380:358–365
-
(2012)
Lancet
, vol.380
, pp. 358
-
-
Hauschild1
-
14
-
-
84895763109
-
-
PID: 24623990, COI: 1:CAS:528:DC%2BC2cXptVKhsbk%3D
-
Khan G, Moss RA, Braiteh F, Saltzman M (2014) Proactive strategies for regorafenib in metastatic colorectal cancer: implications for optimal patient management. Cancer Manag Res 6:93–103
-
(2014)
Cancer Manag Res
, vol.6
, pp. 93
-
-
Khan1
-
15
-
-
84901324490
-
-
PID: 24749649
-
Kudlowitz D, Muggia F (2014) Nanoparticle albumin-bound paclitaxel (nab-paclitaxel): extending its indications. Expert Opin Drug Saf 13:681–685
-
(2014)
Expert Opin Drug Saf
, vol.13
, pp. 681
-
-
Kudlowitz1
-
16
-
-
84892365940
-
-
PID: 24161671, COI: 1:CAS:528:DC%2BC3sXhsleru7vL
-
Kyi C, Postow MA (2014) Checkpoint blocking antibodies in cancer immunotherapy. FEBS Lett 588:368–376
-
(2014)
FEBS Lett
, vol.588
, pp. 368
-
-
Kyi1
-
17
-
-
84892175976
-
-
PID: 24266804, COI: 1:CAS:528:DC%2BC2cXptFarsg%3D%3D
-
Martin-Liberal J, Benson C, Judson I (2014) New drugs in sarcomas. Expert Opin Pharmacother 15:221–229
-
(2014)
Expert Opin Pharmacother
, vol.15
, pp. 221
-
-
Martin-Liberal1
-
18
-
-
84901605959
-
Therapy of mRCC beyond mTOR-inhibition in clinical practice: results of a retrospective analysis
-
Maute L, Grunwald V, Weikert S et al (2014) Therapy of mRCC beyond mTOR-inhibition in clinical practice: results of a retrospective analysis. J Cancer Res Clin Oncol 140:823–827
-
(2014)
J Cancer Res Clin Oncol
, vol.140
, pp. 823-827
-
-
Maute, L.1
Grunwald, V.2
Weikert, S.3
-
19
-
-
84896714827
-
-
PID: 24508103, COI: 1:CAS:528:DC%2BC2cXisFersrg%3D
-
McArthur GA, Chapman PB, Robert C et al (2014) Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study. Lancet Oncol 15:323–332
-
(2014)
Lancet Oncol
, vol.15
, pp. 323
-
-
McArthur1
-
20
-
-
84884721380
-
-
PID: 23942774, COI: 1:STN:280:DC%2BC3sfpsVanuw%3D%3D
-
McDermott D, Haanen J, Chen TT et al (2013) Efficacy and safety of ipilimumab in metastatic melanoma patients surviving more than 2 years following treatment in a phase III trial (MDX010–20). Ann Oncol 24:2694–2698
-
(2013)
Ann Oncol
, vol.24
, pp. 2694
-
-
McDermott1
-
21
-
-
84883021976
-
-
PID: 23560546, COI: 1:CAS:528:DC%2BC3sXhtlalt7jO
-
Mouhayar E, Durand JB, Cortes J (2013) Cardiovascular toxicity of tyrosine kinase inhibitors. Expert Opin Drug Saf 12:687–696
-
(2013)
Expert Opin Drug Saf
, vol.12
, pp. 687
-
-
Mouhayar1
-
22
-
-
84873974299
-
-
O’Bryant CL, Wenger SD, Kim M, Thompson LA (2013) Crizotinib: a new treatment option for ALK-positive non-small cell lung cancer. Ann Pharmacother 47:189–197
-
(2013)
Ann Pharmacother
, vol.47
, pp. 189
-
-
O1
-
23
-
-
84886443514
-
-
PID: 24089443, COI: 1:CAS:528:DC%2BC3sXhsFyns7bM
-
Ott PA, Hodi FS, Robert C (2013) CTLA-4 and PD-1/PD-L1 blockade: new immunotherapeutic modalities with durable clinical benefit in melanoma patients. Clin Cancer Res 19:5300–5309
-
(2013)
Clin Cancer Res
, vol.19
, pp. 5300
-
-
Ott1
-
24
-
-
84885101825
-
-
PID: 23658121, COI: 1:CAS:528:DC%2BC3sXhsl2nsbzL
-
Saji S (2013) Evolving approaches to metastatic breast cancer patients pre-treated with anthracycline and taxane. BioDrugs 27:469–478
-
(2013)
BioDrugs
, vol.27
, pp. 469
-
-
Saji1
-
25
-
-
84906929620
-
-
PID: 24756806
-
Schulze M, Stock C, Zaccagnini M et al (2014) Temsirolimus. Recent Results Cancer Res 201:393–403
-
(2014)
Recent Results Cancer Res
, vol.201
, pp. 393
-
-
Schulze1
-
26
-
-
84895459037
-
-
Sebastian M, Schmittel A, Reck M (2014) First-line treatment of EGFR-mutated nonsmall cell lung cancer: critical review on study methodology. Euro Res Rev 23:92–105
-
(2014)
Euro Res Rev
, vol.23
, pp. 92
-
-
Sebastian1
-
27
-
-
84898994085
-
-
PID: 24790651, COI: 1:CAS:528:DC%2BC2cXhs1Okur%2FE
-
Serrano C, George S (2014) Recent advances in the treatment of gastrointestinal stromal tumors. Ther Adv Med Oncol 6:115–127
-
(2014)
Ther Adv Med Oncol
, vol.6
, pp. 115
-
-
Serrano1
-
28
-
-
84862859820
-
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer
-
Topalian SL, Hodi FS, Brahmer JR et al (2012) Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 366:2443–2454
-
(2012)
N Engl J Med
, vol.366
, pp. 2443-2454
-
-
Topalian, S.L.1
Hodi, F.S.2
al, B.J.R.3
-
29
-
-
84899115962
-
-
PID: 24605265
-
Vacchelli E, Aranda F, Eggermont A et al (2014) Trial watch: tumor-targeting monoclonal antibodies in cancer therapy. Oncoimmunology 3:e27048
-
(2014)
Oncoimmunology
, vol.3
, pp. e27048
-
-
Vacchelli1
-
30
-
-
84886741654
-
Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine
-
Von Hoff DD, Ervin T, Arena FP et al (2013) Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med 369:1691–1703
-
(2013)
N Engl J Med
, vol.369
, pp. 1691-1703
-
-
Von Hoff, D.D.1
Ervin, T.2
al, A.F.P.3
-
31
-
-
84880054782
-
-
PID: 23774698, COI: 1:CAS:528:DC%2BC3sXpvVOks7g%3D
-
Zagouri F, Sergentanis TN, Chrysikos D et al (2013) Molecularly targeted therapies in metastatic pancreatic cancer: a systematic review. Pancreas 42:760–773
-
(2013)
Pancreas
, vol.42
, pp. 760
-
-
Zagouri1
|